WO1999044755A1 - Article medical avec surfaces recouvertes d'un revetement a faible frottement et a faible adsorption proteique - Google Patents

Article medical avec surfaces recouvertes d'un revetement a faible frottement et a faible adsorption proteique Download PDF

Info

Publication number
WO1999044755A1
WO1999044755A1 PCT/DK1999/000093 DK9900093W WO9944755A1 WO 1999044755 A1 WO1999044755 A1 WO 1999044755A1 DK 9900093 W DK9900093 W DK 9900093W WO 9944755 A1 WO9944755 A1 WO 9944755A1
Authority
WO
WIPO (PCT)
Prior art keywords
coating
component
medical article
article according
poly
Prior art date
Application number
PCT/DK1999/000093
Other languages
English (en)
Inventor
Thomas Buch-Rasmussen
Patric Jannasch
Erling BONNE JØRGENSEN
Ib Johannesen
Sokol Ndoni
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to AU32480/99A priority Critical patent/AU3248099A/en
Priority to EP99937894A priority patent/EP1060031B1/fr
Priority to AT99937894T priority patent/ATE248662T1/de
Priority to DE69910982T priority patent/DE69910982T2/de
Priority to JP2000534345A priority patent/JP2002505177A/ja
Publication of WO1999044755A1 publication Critical patent/WO1999044755A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
    • A61M5/31513—Piston constructions to improve sealing or sliding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A61J1/062—Carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/3129—Syringe barrels
    • A61M2005/3131—Syringe barrels specially adapted for improving sealing or sliding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M5/2448—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic comprising means for injection of two or more media, e.g. by mixing

Definitions

  • the present invention relates to a medical article for containing a pharmaceutical protein preparation comprising at least a first component and a second component, having at least one surface coated with a coating to reduce the friction between the two components and to reduce the protein adsorption to the coating.
  • the described coatings are particularly useful for coating containers for storage and administration of liquid protein solutions, such as insulin formulations.
  • Protein formulations are mostly dosed from relatively small containers, i.e. up to 5 ml, and many of the containers are designed for multiple dosages, each dosage often being in the range of 0.1 ml or even less.
  • Such containers equipped with stoppers require a smooth sliding movement of one component, e. g. a stopper, in contact with another component, e. g. a container wall, to provide reliable dosages with high precision.
  • a static friction force a certain applied force
  • the phenomenon causes a sudden, rapid relative movement of the two surfaces. Frequently, the movement stops and another resistance is built up. This kind of movement is generally known as the 'slip-stick' phenomenon and is caused by a degree of adhesion between the components.
  • Today large amounts of insulin are sold in dispensing devices.
  • the insulin is filled in glass containers, which are equipped with rubber stoppers, and these containers are then loaded into dispensing devices.
  • both the glass containers and the rubber stoppers are coated with silicon oil, poly(dimethyl siloxane) (PDMS), to reduce the friction between the container wall and the stopper.
  • PDMS poly(dimethyl siloxane)
  • One common method to coat glass containers with silicon oil is to apply a PDMS-in-water emulsion and subsequently evaporate the water in an oven.
  • US 4,767,414 suggests a coating of a medical container having re- prised friction between the components wherein a surface is plasma-treated as well as a lubricant at one of the components is plasma-treated to inhibit migration of the lubricant into the content of the container.
  • the lubricant is disclosed to reduce the friction between a container wall and a stopper compared to untreated containers and stoppers.
  • the reference does not discuss adherence of proteins.
  • Another reference US 5,338,312 discloses an article having a coating with two or more layers of lubricant securing a low friction force at different movement velocities, in that one layer may secure low friction at low velocities and the other(s) at other velocities. The adherence of protein molecules to the coating is not disclosed.
  • An aspect, which should be considered, when dispensing protein formulations is the events occurring at the surface between the protein solution and the container material that play a crucial role for the overall performance of biological material.
  • the drug is in contact with a packaging material for a long time during storage which is often the case with protein formulations that are filled into the containers immediately after molding of the containers, the stability and life-time of the drug will be affected.
  • the primary reason for this is that protein may be adsorbed to the surfaces of the container, where it is deactivated or denaturated. In this way, layers of deactivated and inaccessible protein are built up at the container surface. This will lead to a loss in protein activity and an enhanced risk of incorrect dosage, due to lowering of the concentration of soluble protein.
  • adsorbed insulin may desorb and some molecules will associate with other deactivated molecules and form aggregates.
  • Aggregates such as fibrils or gel-like particles, form as a result of lower degree of water solubility 3 and aggregation after denaturation.
  • Aggregation of insulin is thought to be an auto- catalyzed process, and leads to an overall destabilization of the insulin formulation. When these aggregates become large enough, they can be seen visually.
  • the propensity of the in- sulin molecule to change its conformation is removed. The result is a significant improvement of the drug stability.
  • the presence of protein aggregates may lead to immunological reactions in the patient, which is unacceptable.
  • Addition of glycerol and certain polysaccarides are well known methods to improve the stability. Further, addition of zinc and calcium ions significantly stabilizes the insulin by promoting the formation of more stable species, i. e., dimers and hexam- ers. It is also known that low concentrations of lecithins or synthetic detergents has a markedly positive effect on the stability of insulin. This effect is thought to be coupled to their ability to cover hydrophobic domains exposed by the insulin molecules. These hydrophobic domains are thought to be involved in the destabilization of insu- lin.
  • non-ionic surfactants In relation to insulin, different kinds of non-ionic surfactants have been used to stabilize insulin formulation, e. g., ethoxylated fatty acids and Pluronics®. Chawla et al. (Diabetes Vol 34, May 1985, pp 420-424) was able to stabilize insulin in PS and PP containers by adding Pluronic® F68, a non-ionic surfactant containing PEO. These types of molecules are however only loosely adsorbed to the surfaces, and are probably present in the insulin solution which results in injection of the polymer when the protein formulation is injected. It is therefore unclear whether the surfactants cover the hydrophobic domains of the insulin, or the hydrophobic plastic surface. Chawla et al. also found that other types of Pluronics®, 17R8 and 25R5, did not stabilize the insulin formulations.
  • the object of the invention is obtained by a medical article for containing a pharmaceutical protein preparation comprising at least a first component and a second component, which is in frictional engagement with said first component, wherein at least one surface on either the first or the second component or both is coated independently with a hydrophilic coating whereby
  • the hydrophilicity of the surface of the coating as measured by the water contact angle is below 90 °
  • the coatings according to the present invention are especially suited for permanently coating internal surfaces of containers equipped with stoppers for storage and administration of liquid protein preparations, such as insulin preparations.
  • the term “long term static friction forces” is meant the friction forces necessary to move the two components relative to each other measured after a resting period of at least 14 days after the components have been brought into frictional engagement with another.
  • the present coating the “slip-stick” phenomenon is substantially eliminated.
  • the coating(s) provide low friction between the two components, such as a container wall and a rubber stopper, resulting in high-precision dosing. In addition, they efficiently prevent the adsorption of protein to the container surface, thereby in- creasing the stability and prolonging the storage time of the protein.
  • Another object of the invention is a process of producing a component of a medical article coated as described above, comprising
  • a third object of the invention is a coating as defined above, for articles having at least a first component and a second component, said second component being in frictional engagement with said first component, wherein at least one surface or either the first or the second component or both is coated independently with a hydrophilic coating.
  • Figure 1 shows an example of the first (figure 1A, injection cylinder) and second (figure 1 B, plunger) components according to the invention.
  • the components are shown in longitudinal cross section.
  • the inner diameter of the first component is 9,23 mm and the outer diameter is 11 ,0 mm.
  • the outer diameter D of the second component is 9,6 mm.
  • Figure 2 and Figure 3 show the result of recordings of friction forces where the maximum static forces are indicated with S and the maximum dynamic friction forces are indicated with D for a medical article coated with two different coatings as described in the examples. Detailed description of the invention
  • the present invention relates to a medical article for containing a pharmaceutical protein preparation
  • a medical article for containing a pharmaceutical protein preparation comprising at least a first component and a second component, such as a container and a stopper, which is in frictional engagement with each other, wherein at least one surface on either the container or the stopper or both is coated independently with a hydrophilic coating whereby
  • the hydrophilicity of the surface of the coating as measured by the water contact angle is below 90 °
  • the coating according to the present invention is hydrophilic, or at least the surface part of the coating exposed to the content is hydrophilic. Without being bound by theory it is believed that hydrophobic domains on the protein molecule is responsible for the protein adsorption, and hence, that a certain hydrophilic surface of the coating reduces the adsorption tendency.
  • the present invention relates to a medical article coated with a coating which is hydrophilic to such an extent that the protein adsorption, in particular the insulin absorption is significantly reduced or substantially eliminated.
  • the hydrophilicity as measured by the water contact angle is below 90 °.
  • the water contact angle is preferably below 60 °, more preferably below 20 °, most preferably below 10 °, in order to secure a low protein adsorption.
  • the amount of protein adsorbed to the coating depends on the concentration of protein solution as well as the surface area of the coating in contact with the protein solution. 7
  • a measure of the protein adsorption is obtained by measuring by the insulin adsorption in a container with a standard volume of 3,5 ml, and an internal surface area of 14.1 cm 2 by the procedure as described in example 2.
  • the protein adsorption measured under these conditions is preferably less than
  • 0.5 % such as less than 0.4 %, most preferably less than 0.3 % of the original protein solution.
  • Insulin stability may be measured by assembling containers and plungers, and subse- quently filling the container with Penmix 30/70®. After closing the container with a bromobutyl plate and an aluminum cap, the containers are stored at 37 degree Centigrade and rotated vertically 4 h every 24 h at 30 rotations per minute. The experiment is stopped at the specified time, and the insulin is acidified by an aqueous HCI solution. The remaining percentage of monoinsulin, as compared to the original amount, may be detected by GPC (gel permeation chromatography), and used as a parameter to describe the remaining insulin activity.
  • GPC gel permeation chromatography
  • any hydrophilic coating exhibiting the low protein adsorption, especially insulin adsorption, may be used for coating the surface of the medi- cal article provided the long-term static friction forces between the first and the second component are below 14 N.
  • the coating according to the present invention has a reduced ability of migrating, because it is preferably essentially a solid material and not an oil or a liquid. Fur- thermore, the coating is preferably fixed to the component.
  • the coating does not migrate from the interface between the two components during storage hence the slip-stick phenomenon is significantly reduced or eliminated whereby a high-precise dosing is possible, in particular when dosing small volumes, such as when dosing insulin.
  • the reduced migration tendency reduces the risk of having particles of the coating solubilised or suspended in the protein formulation.
  • the coating material is not not capable of forming an emulsion with the solvent of the protein formulation, such as water, and is not soluble in water.
  • the coating is preferably a silicon-containing coating, such as a poly(dialkyl siloxane) oil or copolymer.
  • the poly(dialkyl siloxane) is selected from poly(dimethyl siloxane) (PDMS), poly(dipropyl siloxane) or poly(dihexyl siloxane).
  • the coating comprises a linear or branched hydrophilized poly(dialkyl siloxane) oil.
  • the viscosity of the oil is preferably above 200,000 centistokes, such as above 500,000 centisto- kes when applied to the component.
  • the coating comprises a crosslinked or gelled silicon oil, such as a hydrophilized poly(dialkyl siloxane) oil, or a mixture of a crosslinked and a non-crosslinked oil.
  • a crosslinked or gelled oil the migra- tion ability of the oil is significantly reduced and the viscosity increased towards infinitely great, i.e. the oil may broadly be looked upon as a solid material.
  • a cross-linked, or cured, silicon oil is typically obtained by applying a linear, or branched, silicon oil with reactive functionalities which are used to cross-link the coating in a subsequent step.
  • a linear, or branched, silicon oil with reactive functionalities which are used to cross-link the coating in a subsequent step.
  • the cross-linkable silicon oil is of medical grade, e. g. MDX® supplied by Dow Corning (MDX4-4159 Fluid).
  • a cross-linked silicon oil may also be obtained by first applying a silicon oil, linear or branched, and secondly irradiating the oil by a high-energy radiation source, e. g. an electron or x-ray source.
  • the coating comprises a hydrophilized poly(dialkyl siloxane) block and graft copolymer.
  • the copolymer may be any block and graft copolymer which comprises polymeric segments of poly(dialkyl siloxane), such as PDMS.
  • the polymeric segments may, for example, be combined with polymeric segments of polystyrene, polyolefins, polyamides, or polyurethane to form the desired copolymer.
  • the copolymer may be prepared by any method available, for example by sequential anionic polymerization, or different grafting procedures.
  • the hydrophilicity of the coating according to the invention may be obtained by any appropriate method.
  • the coating is sub- jected to an oxidative treatment, such as plasma treatment or corona treatment after having been applied to the component.
  • the coating comprises a copolymer which is made hydrophilic by end-capping the copolymer with hydrophilic group or chain segments.
  • the hydrophilic group may, for example, be a negatively charged chemical group or phosphorylcholine (PC) groups, and the chain segment may, for example, be poly(ethylene oxide) (PEO) or poly(2-hydroxyethyl methacrylate) (pHEMA).
  • PC phosphorylcholine
  • the chain segment may, for example, be poly(ethylene oxide) (PEO) or poly(2-hydroxyethyl methacrylate) (pHEMA).
  • the plasma treated surfaces may be modified in order to further decrease the protein adsorption by coupling of hydrophilic polymer segments or functional groups.
  • These polymer segments or functional groups may be of the same kind as those described above, and may further be coupled to the functional groups generated during the plasma treatment.
  • the hydrophilic groups at the coating will tend to seek into the coating leaving the surface hydrophobic due to the hy- drophobicity of the surrounding air. Accordingly, it is of great importance that the coating remains hydrophilic during storage until the medical article is filled with the protein solution. This may be secured by placing the coated article in a hydrophilic environment, such as by filling the medical article with the protein formulation shortly after the coating process.
  • the thickness of the coating depends on the specific coating, and is preferably from 0.005 to 10 ⁇ m, more preferably from 0.01 to 1 ⁇ m.
  • the optimal thickness depends 10 on the dimensions and shape of the components, and it can easily be performed by one skilled in the art. If the coating is too thin the coating may be torn in use, thereby increasing the friction between the two components. When the thickness of the coating has reached a certain plateau value the friction forces are approximately constant even when the thickness is further increased.
  • the coating is preferably as thin as possible to reduce the costs.
  • the thin coating is preferably from 0,005 to 0,4 ⁇ m, such as from 0,015 to 0,25 ⁇ m, more preferably approximately 0,2 ⁇ m.
  • the medical article may be any article wherein two components are in frictional engagement with each other, such as a syringe and plunger, in particular a cartridge with a stopper.
  • the particular form or shape of the components of the article is not crucial for the present inventionen, as long as they fulfill the criteria for their use, e.g. container and fluid-tight stopper in frictional engagement.
  • the first component is preferably a container, such as a cartridge made of a material selected from glass, ceramic, metal and preferably plastic.
  • the plastic may be filled with inorganic or organic filler.
  • the first component is made of plastic material which is an excellent barrier against the contents of the protein solution, e. g. water and preservatives.
  • plastic materials are commercially available, e. g. polypropylene, cyclic polyolefins, polyester resin.
  • the second component is preferably a stopper at least partly made of a flexible material, such as for example a stopper made of any appropriate material with only the contacting surfaces made in a flexible material, such as rubber.
  • a stopper made of any appropriate material with only the contacting surfaces made in a flexible material, such as rubber.
  • An example is a stopper with an O-ring.
  • the stopper may also be made totally of a flexible material, such as rubber.
  • suitable rubber materials are available on the market, such as bromobutyl, Santoprene®, and Trefsin®.
  • the article may further comprise mixing means. It is preferred that the surface of the mixing means is at least partly coated with a coating as defined above. This is especially to reduce the protein adsorption to the mixing means, but it is also of importance that the friction between the mixing means and the other components is re- cuted. 11
  • the medical article according to the present invention is preferably a container 1 and a stopper 4 as depicted in Fig 1 A and Fig. 1 B comprising the cylinder wall 2 and a coating 3 on the inner surface of the cylinder wall 2.
  • Fig. 1 B the stopper 4 is depicted with a rubber end 5 to be inserted in the injection cylinder 1.
  • the diameter D of the stopper is slightly greater than the inner diameter of the injection cylinder to obtain a sufficient liquid tight sliding engagement.
  • the medical article is preferably constructed to avoid leakage of the liquid protein formulation, in particular without leakage between the stopper and the container wall. This is a problem in particular encountered with a container for storing and administrating (injecting) the formulation because the container is filled with the formulation and stored for a longer period before use. Accordingly, the pressure of the stopper against the container wall is adjusted to withstand leakage.
  • the coating may be applied either on both the components, in any combination, or on only one of the mentioned surfaces.
  • a coating according to the invention may be applied on one of the surfaces, while the other surface is coated with un- treated, i.e. not hydrophilized linear or branched silicon oil.
  • at least the component having the largest surface area in contact with the protein formulation is coated according to the invention.
  • the coating is applied to substantially all the surfaces to be in contact with the protein solution, in order to reduce the risk of destabilisation of the protein solution. Furthermore, in order to maintain the low friction and reduced slip-stick phenomenon at any stage of frictional engagement between the two components the coating should be applied to the all the surfaces of at least one component to be in frictional engagement with the other component.
  • the coating on the first component is different from the coating on the second component, at least at the surfaces to be in frictional engagement with each other. 12
  • the coating on the first component and the second component may comprise, for example a hydrophilized poly(dialkyl siloxane) oil and a hydrophilized cross-linked poly(dialkyl siloxane) oil, respectively, or hydrophilized block copolymer and hydrophilized poly(dialkyl siloxane) oil.
  • the object of the present invention is also achieved by a medical article according to the invention coated with a hydrophilic coating on one component and on the other component coated with a coating responsible or substantially responsible for the low friction forces.
  • the static friction force between the first component and the second component increases gradually with the storage time from the moment of frictional engagement of the two components to reach a plateau value approximately 14 days after assembling of the components. Thereafter the static friction force is approximately con- stant. Accordingly, the static friction force measured 14 days after assembling the two components, such as placing a stopper in a container, can be taken as a measure of the long-term static friction forces.
  • the long-term static friction forces between the first and the second component are below 10 N, preferably below 8 N, more preferably below 6 N.
  • the dynamic friction force should preferably be as close to the static friction force as possible to secure an even movement of the second component relative to the first component during an injection.
  • the dynamic friction forces between the first and the second component are below 8 N, such as 6 N, more preferably below 4 N. 13
  • the long-term static friction forces as well as the dynamic friction forces depend on the dimensions of the two components.
  • the long-term static friction forces are measured with a container as described in the Examples.
  • Another aspect of the present invention is a process of producing a component coated as described above said process comprises adding the coating material to the component material prior to molding and subsequently molding the component from the mixture, or molding the component from the component material and subsequently applying the coating material to the at least one surface of the component, and hydrophiiizing the coating material prior to the molding or after the molding.
  • the components of the medical article may be molded by any suitable process, such as injection molding.
  • the coating is applied to the component after the molding of said component.
  • the coating may be applied by any appropriate method, such as dip coating, spray coating or plasma polymerisation.
  • the coating material is preferably applied as a solution and the solvent removed after application, eg. by evaporation.
  • a hydrophilisation step may be accom- plised prior to or after molding.
  • the coating comprises a copolymer being hy- drophilised by end-capping the hydrophilisation step is preferably carried out prior to the coating step.
  • hydrophilisation may take place as described above.
  • the component material and the coating material is mixed before molding and molded as a mixture.
  • the coating material preferably comprises a copolymer, such as a polyolefin-PDMS block copolymer end- capped with a hydrophilic segment or group. During the molding process the coating material will make for the surface of the component forming a coating fixed to the component.
  • Polypropylene (PP) containers depicted in Figure 1 A, with a volume of 3,5 ml, and an internal surface area of 14.1 cm 2 , having an inner diameter of 9.44 mm were used in the evaluation of the different coatings.
  • the diameter D of the stopper was 9.6 mm.
  • Polypropylene (PP) and bromobutyl rubber represents model materials for the container and stopper in the examples.
  • the used silicone oils were Dow Corning DC360 fluid® (DC360) and Dow Corning MDX4-4159 fluid® (MDX).
  • the molecular data of the polystyrene-polydimethylsiloxane (PSPDMS) block copolymer used are shown in Table 1 below. These types of copolymers can be prepared by well-known methods by one skilled in the arts.
  • PP containers and rubber plungers were coated with silicone oil (MDX and DC360) by a dip coating method.
  • the containers were dip coated in heptane solutions of the silicone oils, and the rubber plungers were dip coated in a Dow Corning OS10® fluid solution of the silicone oils.
  • the concentrations were 1 % (w/v) for DC360, and 1 + 1 % (w/v) for the mixture of DC360 and MDX.
  • PP containers were also dip coated in chloroform solutions (1 % w/v) of the polystyrene-polydimethylsiloxane (PSPDMS) block copolymer. The dip coated samples were left to dry in air at ambient temperature. 15
  • Coatings containing MDX were cured by storing the coated containers in an oven at 40 °C for 10 days. A cup of water was placed in the oven to maintain a relative humidity above 30 % during the curing.
  • the plasma treatments were performed by using a laboratory set-up.
  • the gas used in the treatment was a mixture consisting of 80 % argon and 20 % oxygen.
  • the equipment was operated at 40 W, at a pressure of 0.5 bar for 1.5 min.
  • the friction measurements were carried out as follows: After coating, drying, and in some cases curing, the plungers and the containers were assembled. The containers were filled with a commercial liquid insulin solution (Actrapid® from Novo Nordisk A/S, Penmix 30/70 ), sealed with aluminum caps, and stored at 37 °C. After the storage period, the aluminum caps were removed and the dynamic and static friction forces between the plungers and the containers were evaluated by using a Lloyds tensile tester at a constant displacement speed of 100 mm/min.
  • a commercial liquid insulin solution Actrapid® from Novo Nordisk A/S, Penmix 30/70
  • the plunger was pushed down through the container by the tensile tester, and the force to do so was recorded as a function of the displacement.
  • the maximum static friction force was taken as the peak friction force reached shortly after the plunger begins to move, and the maximum dynamic friction force was taken as the maximum friction force reached after the maximum static friction force had been recorded.
  • the friction forces were measured immediately after assembling, and after 14 days to evaluate the influence of storage time on the friction forces. The results are shown in Fig. 2 and Fig. 3. 16
  • Water contact angle measurements were carried out with a Leitz sessile drop contact meter at ambient temperature. A 5 microliter droplet of Milli-Q water were pumped out onto the surface be means of a microsyringe, and the advancing angles were measured. Receding contact angles were measured after the droplet had been in contact with the surface for 60 sec. At least four measurements were made on different positions on each plate.
  • Insulin adsorption was measured by filling coated containers with 125
  • CPM ⁇ -counts per minute
  • the CPM of the washed containers were 17 measured, and the insulin adsorption is reported as percentage of the original insulin solution detected on the ampoules after washing. The average value from measurements on five containers is reported for each given adsorption value.
  • the water contact angle was measured as specified in example 1.
  • the insulin adsorption to the hydrophilic coating is significantly decreased as compared to the coating exhibiting a water contact angle of 105 °.
  • the decrease is more than 30 %.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne un article médical permettant de contenir une préparation protéique pharmaceutique, formé par au moins un premier élément et un second élément, dont au moins une surface est recouverte d'un revêtement réduisant le frottement entre les deux éléments, ainsi que l'adsorption de protéines par le revêtement. Le revêtement est un revêtement hydrophile, le caractère hydrophile de la surface du revêtement tel que mesuré par l'angle de contact avec l'eau étant inférieur à 90°, et les forces de frottement statique à long terme entre le premier et le second élément étant inférieures à 14N. Les revêtements de la présente invention conviennent en particulier pour recouvrir de manière permanente des surfaces intérieures de récipients équipés de bouchons, destinés à la conservation et à l'administration de préparations protéiques liquides, telles que des préparations insuliniques. Le revêtement est de préférence un revêtement renfermant du silicium, tel qu'un copolymère ou une huile poly(dialkyl siloxane). L'invention concerne également un procédé de production d'un élément d'un article médical ainsi recouvert, consistant soit à ajouter la matière de revêtement à la matière de l'élément avant le moulage, puis à mouler l'élément à partir du mélange, soit à mouler cet élément à partir de la matière de l'élément, puis à appliquer la matière de revêtement sur au moins une des surfaces de l'élément, et à hydrophiliser la matière de revêtement avant ou après le moulage. L'invention concerne, en outre, un revêtement ainsi défini destiné à des articles comportant au moins un premier élément et un second élément.
PCT/DK1999/000093 1998-03-06 1999-02-26 Article medical avec surfaces recouvertes d'un revetement a faible frottement et a faible adsorption proteique WO1999044755A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU32480/99A AU3248099A (en) 1998-03-06 1999-02-26 Medical article with coated surfaces exhibiting low friction and low protein adsorption
EP99937894A EP1060031B1 (fr) 1998-03-06 1999-02-26 Article medical avec surfaces recouvertes d'un revetement a faible frottement et a faible adsorption proteique
AT99937894T ATE248662T1 (de) 1998-03-06 1999-02-26 Medizinischer artikel mit beschichteter oberfläche mit niedriger reibung und geringer eiweissadsorption
DE69910982T DE69910982T2 (de) 1998-03-06 1999-02-26 Medizinischer artikel mit beschichteter oberfläche mit niedriger reibung und geringer eiweissadsorption
JP2000534345A JP2002505177A (ja) 1998-03-06 1999-02-26 低摩擦及び低タンパク質吸着力を示す被覆表層を有する医療製品

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK30798 1998-03-06
DK9800731 1998-05-28
DKPA199800731 1998-05-28
DK0307/98 1998-05-28

Publications (1)

Publication Number Publication Date
WO1999044755A1 true WO1999044755A1 (fr) 1999-09-10

Family

ID=26063740

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1999/000093 WO1999044755A1 (fr) 1998-03-06 1999-02-26 Article medical avec surfaces recouvertes d'un revetement a faible frottement et a faible adsorption proteique

Country Status (2)

Country Link
AU (1) AU3248099A (fr)
WO (1) WO1999044755A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1348741A1 (fr) * 2002-03-26 2003-10-01 Nippon Paint Co., Ltd. Revêtements ayant une resistance à la friction diminuée de résistance dans l'eau et procédé pour réduire la resistance à la friction d'un substrat dans l'eau
WO2009053947A2 (fr) * 2007-10-22 2009-04-30 Becton Dickinson France Revêtement de surface pour empêcher la lixiviation cationique
WO2009055427A2 (fr) * 2007-10-22 2009-04-30 Becton, Dickinson And Company Procédés d'évaluation de l'agrégation d'une protéine dans une suspension comprenant un organopolysiloxane et articles médicaux recouverts d'un organopolysiloxane contenant une solution protéique
US7857285B2 (en) 2005-07-13 2010-12-28 Baxter International Inc. Lubricious or/and wettable or/and anti-thrombin elastomeric gland materials in luer activated devices
US7943242B2 (en) 2006-03-30 2011-05-17 Becton, Dickinson And Company Sealing members, articles using the same and methods of reducing sticktion
US8075995B2 (en) 2006-03-30 2011-12-13 Becton, Dickinson And Company Coating system, articles and assembly using the same and methods of reducing sticktion
EP2495002A1 (fr) * 2009-10-28 2012-09-05 Ajinomoto Co., Inc. Seringue, dispositif pour produire un corps de seringue, et procédé pour produire un corps de seringue
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
WO2015136037A1 (fr) * 2014-03-13 2015-09-17 Stevanato Group International A. S. Procédé de manipulation d'une formulation de médicament liquide
EP2371406A4 (fr) * 2008-12-03 2017-08-16 Denka Company Limited Seringue
WO2018157097A1 (fr) * 2017-02-27 2018-08-30 W.L. Gore & Associates, Inc. Dispositifs d'administration médicaux comprenant des cylindres de seringue à faible teneur en lubrifiant
US10914720B2 (en) 2016-02-10 2021-02-09 Becton Dickinson France Method to evaluate the stability of a protein-based formulation
US11945204B2 (en) 2017-12-15 2024-04-02 West Pharmaceutical Services, Inc. Smooth film laminated elastomer articles

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767414A (en) * 1985-05-16 1988-08-30 Becton, Dickinson And Company Ionizing plasma lubricant method
US4844986A (en) * 1988-02-16 1989-07-04 Becton, Dickinson And Company Method for preparing lubricated surfaces and product
EP0338418A1 (fr) * 1988-04-18 1989-10-25 Becton, Dickinson and Company Composition et procédé d'obtention d'un article lubrifié compatible avec le sang
US5338312A (en) * 1992-10-02 1994-08-16 Becton, Dickinson And Company Article having multi-layered lubricant and method therefor
JPH09324171A (ja) * 1996-06-07 1997-12-16 Nippon Sheet Glass Co Ltd 摩擦低減物品

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767414A (en) * 1985-05-16 1988-08-30 Becton, Dickinson And Company Ionizing plasma lubricant method
US4844986A (en) * 1988-02-16 1989-07-04 Becton, Dickinson And Company Method for preparing lubricated surfaces and product
EP0338418A1 (fr) * 1988-04-18 1989-10-25 Becton, Dickinson and Company Composition et procédé d'obtention d'un article lubrifié compatible avec le sang
US5338312A (en) * 1992-10-02 1994-08-16 Becton, Dickinson And Company Article having multi-layered lubricant and method therefor
JPH09324171A (ja) * 1996-06-07 1997-12-16 Nippon Sheet Glass Co Ltd 摩擦低減物品

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1348741A1 (fr) * 2002-03-26 2003-10-01 Nippon Paint Co., Ltd. Revêtements ayant une resistance à la friction diminuée de résistance dans l'eau et procédé pour réduire la resistance à la friction d'un substrat dans l'eau
US7857285B2 (en) 2005-07-13 2010-12-28 Baxter International Inc. Lubricious or/and wettable or/and anti-thrombin elastomeric gland materials in luer activated devices
US9234118B2 (en) 2006-03-30 2016-01-12 Becton, Dickinson And Company Coating system, articles and assembly using the same and methods of reducing sticktion
US8075995B2 (en) 2006-03-30 2011-12-13 Becton, Dickinson And Company Coating system, articles and assembly using the same and methods of reducing sticktion
US8816022B2 (en) 2006-03-30 2014-08-26 Becton, Dickinson And Company Sealing members, articles using the same and methods of reducing sticktion
US8603638B2 (en) 2006-03-30 2013-12-10 Becton, Dickinson And Company Sealing members, articles using the same and methods of reducing sticktion
US7943242B2 (en) 2006-03-30 2011-05-17 Becton, Dickinson And Company Sealing members, articles using the same and methods of reducing sticktion
US8633034B2 (en) 2007-06-25 2014-01-21 Becton, Dickinson And Company Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
WO2009055427A3 (fr) * 2007-10-22 2009-08-06 Becton Dickinson Co Procédés d'évaluation de l'agrégation d'une protéine dans une suspension comprenant un organopolysiloxane et articles médicaux recouverts d'un organopolysiloxane contenant une solution protéique
WO2009053947A3 (fr) * 2007-10-22 2009-07-09 Becton Dickinson France Revêtement de surface pour empêcher la lixiviation cationique
WO2009055427A2 (fr) * 2007-10-22 2009-04-30 Becton, Dickinson And Company Procédés d'évaluation de l'agrégation d'une protéine dans une suspension comprenant un organopolysiloxane et articles médicaux recouverts d'un organopolysiloxane contenant une solution protéique
EP2237038A1 (fr) * 2007-10-22 2010-10-06 Becton, Dickinson and Company Articles médicaux revêtus d'organopolysiloxane contenant une solution de protéine et tensioactif non ionique
WO2009053947A2 (fr) * 2007-10-22 2009-04-30 Becton Dickinson France Revêtement de surface pour empêcher la lixiviation cationique
EP2371406A4 (fr) * 2008-12-03 2017-08-16 Denka Company Limited Seringue
EP2495002A4 (fr) * 2009-10-28 2014-12-31 Ajinomoto Kk Seringue, dispositif pour produire un corps de seringue, et procédé pour produire un corps de seringue
EP2495002A1 (fr) * 2009-10-28 2012-09-05 Ajinomoto Co., Inc. Seringue, dispositif pour produire un corps de seringue, et procédé pour produire un corps de seringue
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
CN105745030B (zh) * 2014-03-13 2022-04-15 斯泰瓦纳托集团国际 A.S. 处理液体药物制剂的方法
CN105745030A (zh) * 2014-03-13 2016-07-06 斯泰瓦纳托集团国际 A.S. 处理液体药物制剂的方法
WO2015136037A1 (fr) * 2014-03-13 2015-09-17 Stevanato Group International A. S. Procédé de manipulation d'une formulation de médicament liquide
US20160251261A1 (en) * 2014-03-13 2016-09-01 Stevanato Group International A.S. Method of Handling a Liquid Drug Formation
US10914720B2 (en) 2016-02-10 2021-02-09 Becton Dickinson France Method to evaluate the stability of a protein-based formulation
US10493207B2 (en) 2017-02-27 2019-12-03 W. L. Gore & Associates, Inc. Medical delivery devices having low lubricant syringe barrels
AU2018224299B2 (en) * 2017-02-27 2020-04-16 W.L. Gore & Associates, Inc. Medical delivery devices having low lubricant syringe barrels
AU2020202193B2 (en) * 2017-02-27 2020-11-05 W.L. Gore & Associates, Inc. Medical delivery devices having low lubricant syringe barrels
EP3597243A1 (fr) * 2017-02-27 2020-01-22 W. L. Gore & Associates Inc Dispositifs d'administration médicaux comprenant des cylindres de seringue à faible teneur en lubrifiant
AU2020205288B2 (en) * 2017-02-27 2021-10-14 W.L. Gore & Associates, Inc. Medical delivery devices having low lubricant syringe barrels
WO2018157097A1 (fr) * 2017-02-27 2018-08-30 W.L. Gore & Associates, Inc. Dispositifs d'administration médicaux comprenant des cylindres de seringue à faible teneur en lubrifiant
AU2022200248B2 (en) * 2017-02-27 2023-08-03 W. L. Gore & Associates, Inc. Medical delivery devices having low lubricant syringe barrels
EP4252788A3 (fr) * 2017-02-27 2023-12-06 W. L. Gore & Associates, Inc. Dispositifs d'administration médicaux comprenant des cylindres de seringue à faible teneur en lubrifiant
US11931553B2 (en) 2017-02-27 2024-03-19 W. L. Gore & Associates, Inc. Medical delivery devices having low lubricant syringe barrels
US11945204B2 (en) 2017-12-15 2024-04-02 West Pharmaceutical Services, Inc. Smooth film laminated elastomer articles

Also Published As

Publication number Publication date
AU3248099A (en) 1999-09-20

Similar Documents

Publication Publication Date Title
US6461334B1 (en) Medical article with coated surfaces exhibiting low friction and protein adsorption
US6482509B2 (en) Coating system providing low friction
EP1060031B1 (fr) Article medical avec surfaces recouvertes d'un revetement a faible frottement et a faible adsorption proteique
US6296893B2 (en) Pharmaceutical packing device comprising a hollow plastic body having an improved internal lubricant layer and method of making same
EP2614847B1 (fr) Système de revêtement, articles et assemblage utilisant celui-ci et procédés de réduction de l'adhérence
US8816022B2 (en) Sealing members, articles using the same and methods of reducing sticktion
ES2431669T3 (es) Componentes médicos que tienen superficies recubiertas que presentan baja fricción y métodos para reducir la adherencia
US4767414A (en) Ionizing plasma lubricant method
WO1999044755A1 (fr) Article medical avec surfaces recouvertes d'un revetement a faible frottement et a faible adsorption proteique
US8802603B2 (en) Medical components having coated surfaces exhibiting low friction and low reactivity
CN104284967B (zh) 用于医用容器的润滑剂涂层
EP1060030B1 (fr) Systeme de revetement a frottement reduit
KR20150013886A (ko) 윤활제 코팅 및 그러한 코팅을 포함하는 의료용 주사 장치
JP2020040731A (ja) 医薬品および化粧品用の摺動層を有する包装材および方法、およびその製造のための調製物
EP0201915B1 (fr) Procédé pour lubrifier faisant usage d'un plasma ionisant
CA3162207A1 (fr) Revetement de modification de surface pour dispositifs medicaux
JP2002291888A (ja) 医療用ゴム及びこれを用いた薬液注入器

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999937894

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999937894

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1999937894

Country of ref document: EP